Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $5000.0.

  • Dianthus Therapeutics' Capital Expenditures fell 8000.0% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $106000.0, marking a year-over-year increase of 2619.05%. This contributed to the annual value of $105000.0 for FY2024, which is 454.55% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' Capital Expenditures stood at $5000.0, which was down 8000.0% from $46000.0 recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Capital Expenditures peaked at $129000.0 during Q2 2022, and registered a low of -$46000.0 during Q3 2022.
  • Moreover, its 4-year median value for Capital Expenditures was $25000.0 (2024), whereas its average is $28600.0.
  • Examining YoY changes over the last 5 years, Dianthus Therapeutics' Capital Expenditures showed a top increase of 24130.43% in 2023 and a maximum decrease of 8372.09% in 2023.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Capital Expenditures stood at $29000.0 in 2022, then plummeted by 65.52% to $10000.0 in 2023, then soared by 210.0% to $31000.0 in 2024, then plummeted by 83.87% to $5000.0 in 2025.
  • Its Capital Expenditures stands at $5000.0 for Q3 2025, versus $46000.0 for Q2 2025 and $24000.0 for Q1 2025.